HMN-214
- CAS No.
- 173529-46-9
- Chemical Name:
- HMN-214
- Synonyms
- CS-25;HMN-214;IVX-214|||HMN214;HMN-214 USP/EP/BP;HMN-214;HMN214;HMN 214;HMN-214 IVX-214 HMN214;HMN-214, 10 mM in DMSO;HMN-214;HMN214;HMN 214;IVX214;IVX-214; HMN214; HMN 214; IVX 214; IVX-214; IVX214;(E)-4-(2-(N-((4-methoxyphenyl)sulfonyl)acetamido)styryl)pyridine 1-oxide
- CBNumber:
- CB22537582
- Molecular Formula:
- C22H20N2O5S
- Molecular Weight:
- 424.47
- MDL Number:
- MFCD12756255
- MOL File:
- 173529-46-9.mol
- MSDS File:
- SDS
| Boiling point | 663.1±65.0 °C(Predicted) |
|---|---|
| Density | 1.24 |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C |
| solubility | ≥21.2 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| form | solid |
| pka | 0.86±0.10(Predicted) |
| color | White to off-white |
| FDA UNII | 94E9UR0RFR |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
HMN-214 price More Price(22)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 26210 | HMN-214 | 173529-46-9 | 5mg | $93 | 2024-03-01 | Buy |
| Cayman Chemical | 26210 | HMN-214 | 173529-46-9 | 25mg | $365 | 2024-03-01 | Buy |
| Cayman Chemical | 26210 | HMN-214 | 173529-46-9 | 1mg | $32 | 2024-03-01 | Buy |
| Cayman Chemical | 26210 | HMN-214 | 173529-46-9 | 10mg | $169 | 2024-03-01 | Buy |
| TRC | H456360 | HMN214 | 173529-46-9 | 5mg | $100 | 2021-12-16 | Buy |
HMN-214 Chemical Properties,Uses,Production
Description
HMN-214 is an orally bioavailable prodrug form of HMN-176, an indirect inhibitor of polo-like kinase (PLK) activity that inhibits proliferation of a variety of cancer cells. HMN-214 decreases the expression of multidrug resistance gene 1 (MDR1) in AB-A.1 cells and in tumors isolated from mice bearing multidrug-resistant KB-A1 xenografts. HMN-214 (20 mg/kg per day) reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models. It does not decrease nerve conduction velocity or compound action potential amplitude in rabbit sciatic nerves in vivo when administered at a concentration of 30 mg/kg per day.
Uses
HMN 214 is a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. It is a prodrug of HMN 176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1 (PLK1).
Definition
ChEBI: N-(4-methoxyphenyl)sulfonyl-N-[2-[2-(1-oxido-4-pyridin-1-iumyl)ethenyl]phenyl]acetamide is a sulfonamide.
in vitro
hmn-176 showed potent cytotoxicity, with a mean ic50 of 118 nm. the cytotoxic effecacy of hnm-176 was superior to that of adm, vp-16 and cddp, but inferior to that of taxol and vcr. hmn-176 showed less vaiance in log(ic50) than did the reference agents. in addition, judging by its low resistance indices, hmn-176 was more cytotoxic toward the drug-resistant phenotypes of tumor cells than were the other agents tested [1].
in vivo
pk studies showed that hnm-214 was an acceptable oral prodrug of hmn-176. in the in vivo analysis of the schedule-dependency of hmn-214, the repeated administration for over 5 days elicited potent antitumor activity, as expected from the exposure-dependency of the cytotoxicity of hmn-176 and from the cytometric studies. the antitumor activity of hmn-214 against human tumor xenografts was equal or superior to that of clinically avaiable agents, including cis-platinum, adriamycin, vincristine and uft without severe toxicity such as neurotoxicity [1].
target
PLK1
IC 50
hmn-176 showed potent cytotoxic activity against several tumor cell lines with an average ic50 of 118 nmol/l
References
[1] takagi m, honmura t, watanabe s, yamaguchi r, nogawa m, nishimura i, katoh f, matsuda m, hidaka h. in vivo antitumor activity of a novel sulfonamide, hmn-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, hmn-176. invest new drugs. 2003 nov;21(4):387-99.
[2] garland ll, taylor c, pilkington dl, cohen jl, von hoff dd. a phase i pharmacokinetic study of hmn-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. clin cancer res. 2006 sep 1;12(17):5182-9.
HMN-214 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 | linda@hubeijusheng.com | CHINA | 28172 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19552 | 58 |
| SHANGHAI T&W PHARMACEUTICAL CO., LTD. | +86-021-61551413 +8618813727289 | contact@trustwe.com | China | 5738 | 58 |
| Tianjin Xinshengjiahe Science & Technology Development Co,.Ltd | +86-86-22-87899925 +86-8618522618860 | 18522618860@163.com | China | 694 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32202 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30230 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 22854 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10473 | 58 |
173529-46-9(HMN-214)Related Search:
1of2